EBR Systems Reports Implant Shortfall as September Activity Halves
EBR: $0.165 +22.22% · MC: $113M
EBR Systems said third-quarter WiSE implant volumes fell below expectations, with September activity approximately half the average monthly level in July and August. The company is recruiting a new chief commercial officer and reported positive early results in the fourth quarter following a realignment of its US commercial team. Medicare reimbursement for eligible procedures has increased, while a proposed national coverage decision is expected in early December. EBR expects approval of its new manufacturing site by year-end, subject to FDA review, and held approximately A$137 million in cash and securities at the end of September after completing a A$150 million capital raising.

Comments